Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Revista Colombiana de Cardiología
versión impresa ISSN 0120-5633
Resumen
MANZUR, Fernando; VILLARREAL, Tatiana y MONERIZ, Carlos. Dual inhibition of neprilysin and angiotensin II receptor: promising new strategy in the treatment of cardiovascular disease. Rev. Colomb. Cardiol. [online]. 2013, vol.20, n.6, pp.386-393. ISSN 0120-5633.
Neprilysin inhibition and angiotensin II receptor blockade offer potential benefits for the treatment of cardiovascular diseases. The compound LCZ696 is the first drug under study phase as an inhibitor of neprilysin and angiotensin receptors . The increase of the concentration of the natriuretic peptides through the inhibition of neprilysin represents a therapeutic approach which has the potential of conferring cardiac, renal and vascular protection. However, several studies show that the clinical benefits of neprilysin inhibition can be better utilized if the renin-angiotensin system is simultaneously inhibited. This review realized in PubMed aims to present the promising advances in the dual mechanism of inhibition of neprilysin and angiotensin II receptor for the treatment of hypertension and heart failure.
Palabras clave : angiotensin; hypertension; heart failure; natriuretic peptides.